Cyclone Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 28-12-2024
- Paid Up Capital ₹ 0.10 M
as on 28-12-2024
- Company Age 13 Year, 10 Months
- Last Filing with ROC 31 Mar 2024
- Revenue 44.71%
(FY 2020)
- Profit -394.44%
(FY 2020)
- Ebitda -538.34%
(FY 2020)
- Net Worth -510.39%
(FY 2020)
- Total Assets 1331.19%
(FY 2020)
About Cyclone Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Balvant Nawale and Sachin Bhalekar serve as directors at the Company.
- CIN/LLPIN
U74900PN2011PTC138608
- Company No.
138608
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
21 Feb 2011
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Pune
Industry
Company Details
- Location
Pune, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Cyclone Pharmaceuticals Private Limited offer?
Cyclone Pharmaceuticals Private Limited offers a wide range of products and services, including Company Law & Labour Law Consultants, Statutory Compliance Services, Medical Consultants & Clinics, Medical Consultancy Services.
Who are the key members and board of directors at Cyclone Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Balvant Nawale  | Additional Director | 20-Aug-2020 | Current |
| Sachin Bhalekar | Director | 21-Feb-2011 | Current |
Financial Performance of Cyclone Pharmaceuticals.
Cyclone Pharmaceuticals Private Limited, for the financial year ended 2020, experienced significant growth in revenue, with a 44.71% increase. The company also saw a substantial fall in profitability, with a 394.44% decrease in profit. The company's net worth observed a substantial decline by a decrease of 510.39%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Cyclone Pharmaceuticals?
In 2020, Cyclone Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Prajprime Pharmaceuticals (Opc) Private LimitedActive 3 years 6 months
Sachin Bhalekar is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Cyclone Pharmaceuticals?
Cyclone Pharmaceuticals has a workforce of 0 employees as of Apr 04, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Cyclone Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Cyclone Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
